About Dr. Zhang Zhen
Dr. Zhang Zhen (章真) is a Professor, Doctoral Supervisor, and one of China's leading radiation oncologists, based at the Department of Radiation Oncology, Fudan University Shanghai Cancer Center (FUSCC). With extensive clinical and research expertise in the precision radiotherapy management of gastrointestinal cancers — particularly rectal cancer, esophageal cancer, and gastric cancer — as well as breast cancer, gynecological cancers, and other solid tumors, Dr. Zhang is recognized as a senior authority in radiation oncology at China's foremost dedicated cancer center. Her clinical practice is defined by a commitment to evidence-based, multidisciplinary radiotherapy integration, with particular expertise in the use of neoadjuvant chemoradiotherapy to downstage locally advanced tumors and enable curative resection, and in the application of stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT) for precise tumor targeting with maximal normal tissue sparing.
Radiation oncology has been transformed over the past two decades by the development of image-guided radiotherapy (IGRT), intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic body radiotherapy (SBRT), and proton therapy — techniques that enable the precise delivery of high radiation doses to tumors while minimizing dose to surrounding normal tissues. The integration of these advanced radiotherapy techniques with systemic therapy — chemotherapy, targeted therapy, and immunotherapy — in carefully designed multimodal treatment strategies has produced dramatic improvements in local control and survival for patients with locally advanced solid tumors. Dr. Zhang's expertise in the design and delivery of these complex multimodal treatment strategies, supported by FUSCC's state-of-the-art radiotherapy infrastructure, provides international patients with access to the most advanced radiation oncology practice available in China.
Hospital Affiliation: Department of Radiation Oncology, Fudan University Shanghai Cancer Center
Fudan University Shanghai Cancer Center (FUSCC) is China's foremost dedicated cancer center and one of the highest-volume cancer treatment institutions in Asia, managing tens of thousands of new cancer cases annually across all major tumor types. Its Department of Radiation Oncology is one of the largest and most technologically advanced radiation oncology departments in China, equipped with multiple linear accelerators including machines capable of IMRT, VMAT, IGRT, and stereotactic radiosurgery/SBRT; a dedicated stereotactic radiosurgery unit; a brachytherapy suite for gynecological and prostate brachytherapy; and a comprehensive treatment planning infrastructure with the latest generation of treatment planning systems for IMRT, VMAT, SBRT, and adaptive radiotherapy. The department participates actively in national and international clinical trials of novel radiotherapy techniques and radiotherapy-systemic therapy combinations, and maintains active research collaborations with radiation oncology centers across China and internationally.
Clinical Specialties: What Dr. Zhang Zhen Treats
- Rectal cancer radiotherapy — neoadjuvant long-course chemoradiotherapy (LCRT) for locally advanced rectal cancer (T3-4 or N+) to downstage and enable sphincter-preserving surgery; short-course radiotherapy (SCRT) with delayed surgery for selected patients; total neoadjuvant therapy (TNT) combining neoadjuvant chemotherapy and chemoradiotherapy for high-risk locally advanced rectal cancer; watch-and-wait strategy for clinical complete responders after TNT; adjuvant radiotherapy for high-risk resected rectal cancer; SBRT for oligometastatic rectal cancer; coordination with colorectal surgery and medical oncology for multimodal rectal cancer management
- Esophageal cancer radiotherapy — definitive chemoradiotherapy for unresectable or medically inoperable esophageal cancer; neoadjuvant chemoradiotherapy for locally advanced resectable esophageal cancer; IMRT and VMAT for precise esophageal tumor targeting with cardiac and pulmonary sparing; coordination with thoracic surgery and medical oncology for multimodal esophageal cancer management
- Gastric cancer radiotherapy — neoadjuvant chemoradiotherapy for locally advanced gastric cancer; adjuvant chemoradiotherapy after D2 gastrectomy for high-risk resected gastric cancer; palliative radiotherapy for bleeding, obstruction, and pain from advanced gastric cancer; coordination with gastric surgery and medical oncology
- Breast cancer radiotherapy — adjuvant whole-breast radiotherapy after breast-conserving surgery; hypofractionated whole-breast radiotherapy; partial breast irradiation for selected low-risk patients; post-mastectomy chest wall and regional nodal radiotherapy; internal mammary node irradiation for high-risk patients; IMRT and prone positioning for cardiac and pulmonary dose reduction; coordination with breast surgery and medical oncology for multimodal breast cancer management
- Gynecological cancer radiotherapy — definitive chemoradiotherapy for locally advanced cervical cancer including external beam IMRT and image-guided adaptive brachytherapy (IGABT); adjuvant radiotherapy for high-risk endometrial cancer after hysterectomy; vaginal brachytherapy for intermediate-risk endometrial cancer; radiotherapy for vaginal and vulvar cancer; coordination with gynecological oncology and medical oncology
- Stereotactic body radiotherapy (SBRT) — SBRT for early-stage medically inoperable non-small cell lung cancer; SBRT for oligometastatic disease including liver, lung, adrenal, and lymph node metastases; SBRT for locally recurrent tumors after prior radiotherapy; SBRT for pancreatic cancer as definitive or neoadjuvant treatment; spine SBRT for vertebral metastases
- Palliative radiotherapy — palliative radiotherapy for bone metastases including single-fraction and multi-fraction regimens; spinal cord compression management; brain metastasis radiotherapy including whole-brain radiotherapy and stereotactic radiosurgery; palliative radiotherapy for bleeding, obstruction, and pain from advanced tumors
Why International Patients Choose Dr. Zhang Zhen and FUSCC
International patients seek radiation oncology consultation with Dr. Zhang Zhen and FUSCC for reasons that reflect both the clinical depth of her expertise in gastrointestinal and gynecological cancer radiotherapy and the state-of-the-art radiotherapy infrastructure available at China's foremost cancer center.
For patients with locally advanced rectal cancer, Dr. Zhang's expertise in total neoadjuvant therapy — the most current evidence-based approach for high-risk locally advanced rectal cancer, combining neoadjuvant chemotherapy and chemoradiotherapy before surgery — and in the watch-and-wait strategy for clinical complete responders provides access to the most advanced rectal cancer management paradigm, which may not yet be standard practice at the patient's home institution. The combination of Dr. Zhang's clinical expertise and FUSCC's multidisciplinary colorectal cancer team provides a level of rectal cancer management sophistication that is available at only a small number of centers in China.
For patients with oligometastatic disease — a limited number of metastatic sites that may be amenable to ablative local therapy with SBRT — Dr. Zhang's expertise in SBRT for liver, lung, and other oligometastatic sites provides access to a potentially curative or disease-controlling local treatment strategy that is increasingly supported by randomized trial evidence but remains underutilized in many oncology settings. The cost of radiation oncology consultation and radiotherapy at FUSCC is substantially below that of equivalent care in Western healthcare systems, and access to specialist consultation can typically be arranged within days through CMCS.
What to Expect at Your Consultation
Consultations with Dr. Zhang Zhen at FUSCC arranged through CMCS begin with a comprehensive review of all prior oncological records — including staging imaging (CT, MRI, PET-CT), pathology and molecular profiling results, prior treatment records including surgery, chemotherapy, and prior radiotherapy, and relevant laboratory investigations. CMCS will arrange certified translation of all medical records and imaging reports in advance of the consultation. Dr. Zhang will assess the tumor stage and treatment history, evaluate the role and optimal technique of radiotherapy in the overall treatment strategy, outline the recommended radiotherapy approach with detailed rationale, and coordinate multidisciplinary tumor board review. A written English-language consultation summary is provided after every appointment, and CMCS will facilitate direct communication between Dr. Zhang's team and the patient's home oncologist for continuity of care planning.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking radiation oncology consultation with Dr. Zhang Zhen at Fudan University Shanghai Cancer Center. Our services include priority consultation scheduling, certified medical record and imaging report translation, coordination of additional staging investigations, on-site interpretation, radiotherapy planning and treatment coordination, and written English-language reporting of all findings and recommendations.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
0 comments